![Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type [Type 1 Collagen and Hyaluronic Acid], End User, and Country- Product Image](http://www.researchandmarkets.com/product_images/12694/12694101_500px_jpg/europe_intraarticular_injection_for_osteoarticular_infiltrations_market.jpg)
The Europe intra-articular injection for osteoarticular infiltrations market size is expected to grow from US$ 97.43 million in 2023 to US$ 157.08 million by 2031; it is projected to register a CAGR of 6.2% during 2023-2031.
Intra-articular injections for osteoarthritis are a medical procedure where medication is injected directly into a joint affected by osteoarthritis. This approach is intended to reduce pain and improve joint function. Increasing awareness among healthcare professionals and patients regarding the benefits of these injections, combined with increasing investment in healthcare infrastructure and innovation, is facilitating increased access to these treatments.
The increasing prevalence of osteoarthritis and advancements in injection techniques are noteworthy factors contributing to the expansion of the Europe intra-articular injection for osteoarticular infiltrations market size. However, the side effects associated with intra-articular injections hinder the Europe intra-articular injection for osteoarticular infiltrations market growth.
Intra-articular injections are among the innovative and emerging fields of treatment for osteoarticular infiltrations. Manufacturers are involved in various clinical trials to ensure the safety, efficacy, and reliability of innovative drugs. For instance, in May 2024, the Swedish Company, Synartro, initiated a capital raise of between US$ 3.73 and 7.36 million to conduct a clinical study of the osteoarthritis candidate SYN321. It is in the final phase to secure an EU grant of US$ 2.78 million. Additionally, in April 2023, the company received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start the phase 1/2a first-in-human clinical study of the investigational drug candidate SYN321.
Other market players in the regions are also conducting clinical trials for intra-articular injections, which can lead to the development of innovative products. For instance, in August 2022, Grünenthal, a German company enrolled the first patient in its global clinical Phase III program for resiniferatoxin (RTX). Grünenthal has conducted three trials in ~200 locations across Europe, the US, Latin America, South Africa, and Japan to investigate the safety and effectiveness of intra-articular injections of RTX in adults. The outcomes observed in the trials mainly focus on an improvement in the physical function and pain score in the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index from baseline to 52 weeks.
Upon completion, the Phase III program is intended to provide marketing approval for RTX in Europe, the US, and Japan. The company intends to submit a new drug application in 2024, indicating the potential market entry of RTX in 2025. Therefore, the increasing number of clinical trials are expected to enhance the development of innovative products in the region, which, in turn, will contribute to the Europe intra-articular injection for osteoarticular infiltrations market growth in coming years.
The Centers for Disease Control and Prevention, World Health Organization, and National Center for Biotechnology Information are among the primary and secondary sources referred to while preparing the Europe intra-articular injection for osteoarticular infiltrations market report.
Intra-articular injections for osteoarthritis are a medical procedure where medication is injected directly into a joint affected by osteoarthritis. This approach is intended to reduce pain and improve joint function. Increasing awareness among healthcare professionals and patients regarding the benefits of these injections, combined with increasing investment in healthcare infrastructure and innovation, is facilitating increased access to these treatments.
The increasing prevalence of osteoarthritis and advancements in injection techniques are noteworthy factors contributing to the expansion of the Europe intra-articular injection for osteoarticular infiltrations market size. However, the side effects associated with intra-articular injections hinder the Europe intra-articular injection for osteoarticular infiltrations market growth.
Intra-articular injections are among the innovative and emerging fields of treatment for osteoarticular infiltrations. Manufacturers are involved in various clinical trials to ensure the safety, efficacy, and reliability of innovative drugs. For instance, in May 2024, the Swedish Company, Synartro, initiated a capital raise of between US$ 3.73 and 7.36 million to conduct a clinical study of the osteoarthritis candidate SYN321. It is in the final phase to secure an EU grant of US$ 2.78 million. Additionally, in April 2023, the company received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start the phase 1/2a first-in-human clinical study of the investigational drug candidate SYN321.
Other market players in the regions are also conducting clinical trials for intra-articular injections, which can lead to the development of innovative products. For instance, in August 2022, Grünenthal, a German company enrolled the first patient in its global clinical Phase III program for resiniferatoxin (RTX). Grünenthal has conducted three trials in ~200 locations across Europe, the US, Latin America, South Africa, and Japan to investigate the safety and effectiveness of intra-articular injections of RTX in adults. The outcomes observed in the trials mainly focus on an improvement in the physical function and pain score in the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index from baseline to 52 weeks.
Upon completion, the Phase III program is intended to provide marketing approval for RTX in Europe, the US, and Japan. The company intends to submit a new drug application in 2024, indicating the potential market entry of RTX in 2025. Therefore, the increasing number of clinical trials are expected to enhance the development of innovative products in the region, which, in turn, will contribute to the Europe intra-articular injection for osteoarticular infiltrations market growth in coming years.
Type-Based Insights
Based on type, the Europe intra-articular injection for osteoarticular infiltrations market is segmented into Type 1 collagen and hyaluronic acid. The hyaluronic acid segment held the largest Europe intra-articular injection for osteoarticular infiltrations market share in 2023 Hyaluronic acid injections are employed to treat knee pain in patients who were not responsive to other treatment options. Recent advancements in hyaluronic acid injection therapy have significantly expanded growth trajectory. A robust focus on developing and introducing novel products in the market is expected to support the growth of the segment, thereby contributing to market growth.The Centers for Disease Control and Prevention, World Health Organization, and National Center for Biotechnology Information are among the primary and secondary sources referred to while preparing the Europe intra-articular injection for osteoarticular infiltrations market report.
Reasons to buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe intra-articular injection for osteoarticular infiltrations market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe intra-articular injection for osteoarticular infiltrations market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Landscape
5. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Key Market Dynamics
6. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Analysis
7. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Analysis - by Type
8. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market Analysis - by End User
9. Europe Intra-Articular Injection For Osteoarticular Infiltrations Market - Country Analysis
10. Industry Landscape
11. Company Profiles
12. Appendix
List of Tables
List of Figures
Companies Mentioned
Some of the leading companies in the Europe Intra-Articular Injection For Osteoarticular Infiltrations Market include:- Bioventus Inc.
- SEIKAGAKU CORPORATION
- Maxigen Biotech Inc.
- Istem Medical Inc.
- Sanofi SA
- Ferring Pharmaceuticals
- Fidia Pharma USA Inc.
- Biotech Healthcare Group
- Bioteck S.p.A.
- I+MED.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 92 |
| Published | October 2024 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 97.43 Million |
| Forecasted Market Value ( USD | $ 157.08 Million |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 10 |
